tetano
Editor, Senior Moderator
Respirol Case Rep
. 2021 Jun 8;9(7):e00793.
doi: 10.1002/rcr2.793. eCollection 2021 Jul.
Delayed hypercoagulable state in COVID-19 adolescent patient: a case report
Desdiani Desdiani[SUP] 1 2 [/SUP], Nita Yulianti[SUP] 3 [/SUP], Anindita Basuki[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a systemic hyperinflammation disease which can cause severe respiratory symptoms and extrapulmonary manifestations. Hypercoagulable state in COVID-19 adolescent patient is a rare case. We present the case of a 16-year-old Indonesian boy with mild COVID-19 symptoms. Initially, the patient was treated with azithromycin, N-acetyl cysteine, etc. After several days of the treatment, there was clinical improvement. However, on day 15, the patient experienced hypercoagulation and stroke-like symptoms. The patient was then subjected to additional drugs, including low-molecular weight heparin (LMWH), and peripheral neuropathy vitamin therapy. On day 20, the clinical symptoms reduced. This case demonstrates the need for further study of the association between COVID-19 and stroke in young population and the use of anticoagulants to prevent thrombotic events.
Keywords: Adolescent patient; COVID‐19; hypercoagulation.
. 2021 Jun 8;9(7):e00793.
doi: 10.1002/rcr2.793. eCollection 2021 Jul.
Delayed hypercoagulable state in COVID-19 adolescent patient: a case report
Desdiani Desdiani[SUP] 1 2 [/SUP], Nita Yulianti[SUP] 3 [/SUP], Anindita Basuki[SUP] 4 [/SUP]
Affiliations
- PMID: 34136260
- PMCID: PMC8186404
- DOI: 10.1002/rcr2.793
Abstract
Coronavirus disease 2019 (COVID-19) is a systemic hyperinflammation disease which can cause severe respiratory symptoms and extrapulmonary manifestations. Hypercoagulable state in COVID-19 adolescent patient is a rare case. We present the case of a 16-year-old Indonesian boy with mild COVID-19 symptoms. Initially, the patient was treated with azithromycin, N-acetyl cysteine, etc. After several days of the treatment, there was clinical improvement. However, on day 15, the patient experienced hypercoagulation and stroke-like symptoms. The patient was then subjected to additional drugs, including low-molecular weight heparin (LMWH), and peripheral neuropathy vitamin therapy. On day 20, the clinical symptoms reduced. This case demonstrates the need for further study of the association between COVID-19 and stroke in young population and the use of anticoagulants to prevent thrombotic events.
Keywords: Adolescent patient; COVID‐19; hypercoagulation.